News Article

Danish biotechnology company Zealand Pharma has announced a multi-target strategic collaboration with US-based Generate Biomedicines to design and develop novel protein therapeutics for obesity and other metabolic diseases.

Under the terms of the agreement, Generate will receive an upfront payment of $30m and up to $35m in early preclinical milestones for the first two programmes. Generate is also eligible to receive up to nearly $1.2bn in potential development, regulatory, and commercial milestones, bringing the total deal value to $1.265bn alongside tiered royalties on future global sales.

The collaboration is designed to combine Zealand Pharma’s extensive expertise in peptide chemistry and metabolic health with Generate’s proprietary machine learning platform. Under the development framework, Generate will utilise its generative artificial intelligence platform to lead early-stage research through to lead-candidate selection. Once the lead candidates are selected, Zealand Pharma will assume full responsibility and funding for subsequent preclinical testing, clinical development, regulatory submissions, and global commercialisation. The initial focus of the partnership will be to design multispecific protein candidates that can meet or exceed predefined efficacy and tolerability profiles.

For investors and healthcare operators, this high-value alliance underscores how biotechnology companies are aggressively integrating generative AI platforms to shorten lead identification times and expand their therapeutic toolboxes.

Zealand Pharma has built a robust internal pipeline of peptide-based obesity candidates, but the partnership with Generate allows it to expand into complex multispecific proteins that could offer differentiated treatment options complementary to popular incretin-based therapies.

Historically, metabolic drug development has been highly competitive, and incorporating AI-driven molecular design is increasingly seen as a crucial capability to maintain a competitive advantage. The deal also illustrates the growing trend of biopharmaceutical innovators relying on external technology platforms to scale their pipelines while managing development costs through structured, milestone-heavy contracts.